U.S. markets closed

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
3.2645+0.0645 (+2.02%)
At close: 02:08PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.2000
Bid3.0000 x 3200
Ask3.3100 x 900
Day's Range3.1300 - 3.2645
52 Week Range2.8940 - 4.7500
Avg. Volume23,560
Market Cap166.483M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GNFT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Buyers & Sellers for 06/26/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • Zacks

    GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

    After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

  • Benzinga

    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

    Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who have shown inadequate response or intolerance to ursodeoxycholic acid (UDCA), the current standard therapy. PBC is a chronic disease in which the bile ducts in the liver are slowly destroyed. The trial met its primary composite endpoint, with 51% of patients on elafibranor 80mg exhibiting a cholestasis

  • InvestorPlace

    The 7 Best Biotech Stocks to Buy for February 2023

    While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from